Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

rst calendar half of 2009.

PSI-7851

During 2008, Pharmasset nominated PSI-7851 as its lead, second generation nucleotide candidate for HCV. Preclinical data indicate that PSI-7851 could be up to 20 times more potent than R7128, raising the prospect that the drug might be used in fixed dose combinations in the future. The company plans to file an IND for PSI-7851 in the first calendar quarter of 2009.

"During 2008, Pharmasset made significant progress both in the clinic and on the corporate front," said Schaefer Price, Pharmasset's President and CEO. "We remain focused on maintaining this momentum and building a pipeline of differentiated antiviral candidates. Through our collaboration with Roche, the leader in HCV market, we plan to rapidly progress R7128 through phase 2 studies. The partnership is also exploring the paradigm changing model of an all oral (interferon sparing) regimen for HCV, which we believe would be the future of treatment. These efforts provide the groundwork for our next generation of nucleoside and nucleotide inhibitors, such as PSI-7851, that hold the potential for us to explore fixed dosed combinations."

Financial Results

For the fiscal year ended September 30, 2008 Pharmasset reported revenues of $1.9 million, compared with revenues of $22.0 million for the fiscal year 2007. The receipt of milestones totaling $20 million from Roche led to higher reported revenues in the fiscal year 2007.

Total costs and expenses for the fiscal year ended September 30, 2008 were $56.3 million as compared to $29.5 million for the same period in 2007. The increased operating expenses for fiscal year 2008 were primarily the result of an increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic HBV infection, as well as increased drug discovery activities and the administrative expenses of a public company.


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  Luminex Corporation (NASDAQ: ... the Morgan Stanley Global Healthcare Conference to be held ... Hotel in New York City . ... a.m. Eastern time on Friday, September 18, 2015.  The ... Luminex Corporation,s website at http://www.luminexcorp.com . Simply log on ...
(Date:9/4/2015)... , September 4, 2015 ... by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by ... and by Product - Global Forecast to 2020", published ... reach USD 2.5 Billion by 2020, growing at a ... to 2020. Browse 139 Tables and ...
(Date:9/4/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... Rodman & Renshaw 17 th Annual Global Investment ... New York City .  Dr. Michael Berelowitz ... on September 9, 2015. Presentation Details: ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... UPI ), a medical device company ... to treat voiding dysfunctions, today announced that Noridian ... both regional Medicare carriers, now cover percutaneous, posterior ... Neuromodulation System for the treatment of the symptoms ...
... was voted the most powerful person in healthcare by readers ... business news magazine. It,s the second consecutive year Obama topped ... in Healthcare. "The passage of national healthcare reform ... Modern Healthcare Editor David Burda. "The Patient Protection ...
Cached Medicine Technology:Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 2Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplasty's Urgent® PC Neuromodulation System 3Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year 2
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... a line of personal humidifying medical devices, announced its only mission and research ... Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... development of its first neighborhood created specifically for adults with intellectual, developmental and ... Phoenix Metro area and feature 30 cottage or “pocket” homes. In this community, ...
(Date:9/4/2015)... ... ... and Overseer at The House of Yahweh, has written an open letter to Pope Francis ... United States. , Yisrayl lays out what he says is the true meaning of the ... provides the meaning of his own name and describes what bible prophecy says about his ...
(Date:9/3/2015)... ... ... AlignLife of Wauwatosa is excited to hold its annual Coat Drive ... who don't have the ability to buy a jacket warm enough for the winters ... to help those in need." , This is AlignLife's third annual Coat Drive. Each ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... , a privately held medical technology company that will bring low-cost cancer pre-screening ... worldwide. , Preora’s proprietary and automated technology platform detects and measures cellular ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3
... those passionate about having a child, it’s a research they will ... York hospital plan the first uterus transplant with the aim of ... is not without ethical controversies and technical difficulties though. ... organs do, and would be removed after the recipient gives birth ...
... be best for your health. A new study found that ... to the bacterium Helicobacter pylori, //and younger siblings from large ... type of stomach cancer. ,These latest findings are ... who were followed over a 28-year period. The researchers found ...
... melanoma screening of adults age 50 or older appears ... screening programs, according to an article in the January ... only cancer for which incidence and death rates continue ... to be underused, according to background information in the ...
... Metropolitan police, stating that the establishment of supercasinos has led ... put the spotlight on problem gamblers. ,Doctors from ... and its Treatment within the UK, have urged the National ... for gamblers, as gambling can now be termed ...
... genetically altered chicken eggs that can be used to produce drugs ... Roslin Institute at Edinburgh, Scotland have claimed to create ... be used to create life saving drugs. ,These ... what the National Health Service incurs, according to them. ...
... including Alzheimer’s disease, is one of the most devastating ... individuals in the U.S. and 24 million worldwide, dementia ... to function independently – making it one of people’s ... confusional state, a common and serious complication in older ...
Cached Medicine News:Health News:Uterus Transplant- A Future Reality 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:One-time Melanoma Screening Appears to Be Cost-effective for Elderly People 2Health News:Gambling to Be Taken as a Serious Addiction, Warns BMA 2Health News:No Pills Just Omelets 2Health News:Relationship Between Delirium and Dementia 2Health News:Relationship Between Delirium and Dementia 3Health News:Relationship Between Delirium and Dementia 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: